Stryker Co. (NYSE:SYK) Shares Sold by Perkins Coie Trust Co

Perkins Coie Trust Co lowered its position in shares of Stryker Co. (NYSE:SYK) by 2.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,255 shares of the medical technology company’s stock after selling 322 shares during the period. Perkins Coie Trust Co’s holdings in Stryker were worth $4,052,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Dale Q Rice Investment Management Ltd purchased a new position in Stryker during the 4th quarter worth $587,000. PFW Advisors LLC acquired a new stake in shares of Stryker during the fourth quarter worth about $1,350,000. Parnassus Investments LLC purchased a new position in shares of Stryker during the third quarter worth about $762,798,000. Baltimore Washington Financial Advisors Inc. increased its position in Stryker by 2.4% in the 3rd quarter. Baltimore Washington Financial Advisors Inc. now owns 66,681 shares of the medical technology company’s stock valued at $24,089,000 after acquiring an additional 1,554 shares during the period. Finally, Sivik Global Healthcare LLC raised its stake in Stryker by 8.0% during the 3rd quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the medical technology company’s stock valued at $9,754,000 after acquiring an additional 2,000 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Up 0.6 %

Stryker stock opened at $383.91 on Friday. The firm has a market capitalization of $146.35 billion, a price-to-earnings ratio of 41.15, a price-to-earnings-growth ratio of 2.51 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker Co. has a fifty-two week low of $307.23 and a fifty-two week high of $398.20. The stock’s fifty day moving average is $375.51 and its two-hundred day moving average is $358.81.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same period last year, the firm posted $2.46 EPS. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. Analysts predict that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. This is a positive change from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio is presently 36.01%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Evercore ISI lifted their target price on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Wells Fargo & Company lifted their price objective on shares of Stryker from $405.00 to $427.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Thursday, January 9th. Canaccord Genuity Group lifted their target price on shares of Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Finally, JMP Securities reiterated a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $405.80.

Insider Buying and Selling at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.50% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.